Skip to main content
Figure 1 | Respiratory Research

Figure 1

From: Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways

Figure 1

Effects of RGDS peptide on LPS-induced increases in neutrophil (A, B) and macrophage (C, D) numbers in bronchoalveolar lavage (BAL) fluid. Where indicated, mice were administered i.p. RGDS (1, 2.5 or 5 mg/kg) or RGES (5 mg/kg, a negative control) once 1 h before LPS treatment and sacrificed 4 h post-LPS. Mice were also administered these peptides (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and sacrificed 24 h post-LPS. Values represent means ± SEM of 5 mice per group. *Significantly different from saline treated controls, p < 0.05; +significantly different from animals treated with LPS only, p < 0.05.

Back to article page